Claret Asset Management Corp Has $13.55 Million Holdings in CVS Health Co. (NYSE:CVS)

Claret Asset Management Corp grew its holdings in CVS Health Co. (NYSE:CVS) by 10.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 301,743 shares of the pharmacy operator’s stock after purchasing an additional 28,500 shares during the period. CVS Health comprises 2.1% of Claret Asset Management Corp’s portfolio, making the stock its 14th largest holding. Claret Asset Management Corp’s holdings in CVS Health were worth $13,545,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in CVS. Morse Asset Management Inc purchased a new stake in shares of CVS Health during the third quarter worth $409,000. Westside Investment Management Inc. lifted its holdings in shares of CVS Health by 4.6% during the 3rd quarter. Westside Investment Management Inc. now owns 64,517 shares of the pharmacy operator’s stock valued at $4,041,000 after buying an additional 2,856 shares during the last quarter. World Investment Advisors LLC grew its stake in shares of CVS Health by 280.7% in the 3rd quarter. World Investment Advisors LLC now owns 27,543 shares of the pharmacy operator’s stock valued at $1,732,000 after buying an additional 20,308 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in CVS Health in the third quarter worth approximately $2,071,000. Finally, Tidal Investments LLC lifted its stake in CVS Health by 52.2% in the third quarter. Tidal Investments LLC now owns 112,010 shares of the pharmacy operator’s stock valued at $7,043,000 after acquiring an additional 38,408 shares during the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on CVS. Morgan Stanley restated an “overweight” rating on shares of CVS Health in a report on Tuesday. UBS Group reduced their price target on CVS Health from $62.00 to $59.00 and set a “neutral” rating for the company in a research report on Tuesday, February 11th. Mizuho increased their price objective on CVS Health from $70.00 to $76.00 and gave the company an “outperform” rating in a report on Wednesday, April 9th. Evercore ISI upped their target price on CVS Health from $60.00 to $65.00 and gave the stock an “outperform” rating in a research report on Monday, January 27th. Finally, Piper Sandler lifted their price target on shares of CVS Health from $72.00 to $74.00 and gave the company an “overweight” rating in a research report on Friday, March 21st. Four research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and an average target price of $71.83.

Insider Buying and Selling at CVS Health

In other CVS Health news, Director Michael F. Mahoney purchased 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was acquired at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the acquisition, the director now directly owns 39,356 shares of the company’s stock, valued at $2,625,045.20. This represents a 320.65 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP James David Clark sold 7,513 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares of the company’s stock, valued at $556,941.90. The trade was a 47.23 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.24% of the company’s stock.

CVS Health Price Performance

Shares of CVS Health stock opened at $67.19 on Friday. The firm has a market cap of $84.71 billion, a P/E ratio of 18.36, a price-to-earnings-growth ratio of 0.98 and a beta of 0.57. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. CVS Health Co. has a twelve month low of $43.56 and a twelve month high of $71.45. The firm’s 50-day simple moving average is $66.46 and its 200-day simple moving average is $58.79.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. As a group, research analysts expect that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.96%. The ex-dividend date is Tuesday, April 22nd. CVS Health’s payout ratio is 72.68%.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.